Shares of Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) passed above its fifty day moving average during trading on Friday following a better than expected earnings announcement. The stock has a fifty day moving average of $14.80 and traded as high as $15.08. Terumo shares last traded at $15.05, with a volume of 462,979 shares.
The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). Terumo had a return on equity of 7.03% and a net margin of 9.31%. The company had revenue of $1.96 billion for the quarter, compared to analysts’ expectations of $1.94 billion.
Analyst Ratings Changes
A number of research firms have recently weighed in on TRUMY. Nomura raised Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Zacks Research raised Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the company presently has an average rating of “Strong Buy”.
Get Our Latest Stock Analysis on TRUMY
Terumo Stock Performance
The firm’s 50 day simple moving average is $14.80 and its 200-day simple moving average is $14.09. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.37 and a current ratio of 2.19. The company has a market cap of $22.20 billion, a price-to-earnings ratio of 31.35 and a beta of 0.82.
Terumo Company Profile
Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.
Further Reading
- Five stocks we like better than Terumo
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
